User profiles for M. Elkabets

Moshe Elkabets

Ben-Gurion University of the Negev
Verified email at bgu.ac.il
Cited by 4755

The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions

RN Apte, S Dotan, M Elkabets, MR White… - Cancer and Metastasis …, 2006 - Springer
Interleukin-1 (IL-1) includes a family of closely related genes; the two major agonistic proteins,
IL-1α and IL-1β, are pleiotropic and affect mainly inflammation, immunity and hemopoiesis…

Effects of micro-environment-and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour–host interactions

…, Y Krelin, X Song, S Dotan, E Recih, M Elkabets… - European journal of …, 2006 - Elsevier
Interleukin-1 (IL-1) comprises a family of closely related genes; the two major agonistic
proteins, IL-1α and IL-1β, are pleiotropic and affect mainly inflammation, immunity and …

Molecular pathways: AXL, a membrane receptor mediator of resistance to therapy

M Scaltriti, M Elkabets, J Baselga - Clinical Cancer Research, 2016 - AACR
AXL is a tyrosine kinase membrane receptor that signals via PI3K, MAPK, and protein kinase
C (PKC), among other pathways. AXL has oncogenic potential and interacts with other …

Interleukin-1β–Driven inflammation promotes the development and invasiveness of chemical carcinogen–Induced tumors

…, S Dotan, M Elkabets, E Reich, M Fogel, M Huszar… - Cancer research, 2007 - AACR
The role of microenvironment interleukin 1 (IL-1) on 3-methylcholanthrene (3-MCA)–induced
carcinogenesis was assessed in IL-1–deficient mice, ie, IL-1β −/− , IL-1α −/− , IL-1α/β −/− (…

[PDF][PDF] AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas

M Elkabets, E Pazarentzos, D Juric, Q Sheng… - Cancer cell, 2015 - cell.com
Phosphoinositide-3-kinase (PI3K)-α inhibitors have shown clinical activity in squamous cell
carcinomas (SCCs) of head and neck (H&N) bearing PIK3CA mutations or amplification. …

mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer

M Elkabets, S Vora, D Juric, N Morse… - Science translational …, 2013 - science.org
… For each gene K, we let {k 1 , k 2 , …, k m } be the set of percent knockdowns for the shRNAs
targeting K and let k max denote the maximum percent knockdown in this set. The weights …

IL‐1β regulates a novel myeloid‐derived suppressor cell subset that impairs NK cell development and function

M Elkabets, VSG Ribeiro, CA Dinarello… - European journal of …, 2010 - Wiley Online Library
… Moshe Elkabets was supported by the Chateaubriand scientific pre- and post-doctorate
fellowships 2007-2008, Nehemia-Lev-Zion excellent Ph.D scholarship and ISEF Foundation. …

[HTML][HTML] Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice

M Elkabets, AM Gifford, C Scheel… - The Journal of …, 2011 - Am Soc Clin Investig
Systemic instigation is a process by which endocrine signals sent from certain tumors (instigators)
stimulate BM cells (BMCs), which are mobilized into the circulation and subsequently …

PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D

…, RC Hendrickson, M Elkabets, MN Dickler, M Scaltriti… - Science, 2017 - science.org
Activating mutations in PIK3CA, the gene encoding phosphoinositide-(3)-kinase α (PI3Kα),
are frequently found in estrogen receptor (ER)–positive breast cancer. PI3Kα inhibitors, now …

P-selectin is a nanotherapeutic delivery target in the tumor microenvironment

Y Shamay, M Elkabets, H Li, J Shah, S Brook… - Science translational …, 2016 - science.org
Disseminated tumors are poorly accessible to nanoscale drug delivery systems because of
the vascular barrier, which attenuates extravasation at the tumor site. We investigated P-…